New data, reported for the first time at this year's European Federation of Neurological Societies (EFNS) Annual Meeting in Athens, Greece, support the efficacy and safety of Boehringer Ingelheim's ...

Restless legs syndrome: a new practice guideline Evidence shows strong support for prescribing pramipexole, rotigotine, cabergoline, or gabapentin enacarbil to treat adults with restless legs syndrome ...

The aim of the review was to assess the safety and efficacy of oral and parenteral iron for the treatment of RLS. For patients with restless legs syndrome (RLS), iron therapy may improve both ...

As the COVID-19 pandemic continues to spread, new and unusual chronic sequelae of the disease are cropping up in many medical practices. Now, a new case paper published in The Lancet in September 2020 ...

MIRAPEX ER (pramipexole dihydrochloride) extended-release tablets from Boehringer-Ingelheim The FDA has approved Mirapex ER (pramipexole dihydrochloride extended-release tablets, from ...

NEW YORK (Reuters Health) - The impulsive behavior that sometimes develops as a side effect of treatment with "dopamine agonists" drugs may not be limited just to patients with Parkinson's disease.

The study shows restless legs syndrome is associated with higher Parkinson's disease incidence, raising questions about treatment impacts on symptoms.